UAS Laboratories Overview
- Founded
-
1979
- Status
-
Acquired/Merged
- Employees
-
230
- Latest Deal Type
-
M&A
- Financing Rounds
-
5
- Investments
-
3
UAS Laboratories General Information
Description
Manufacturer of probiotic products intended to provide trusted probiotic based facilities through the creative application of science, quality and talent that promote healthy living, while exceeding stakeholder expectations. The company specializes in semi-finished and raw-material supplies of probiotic-based supplements and private labeling, providing biotechnology focused research on human health to the healthcare industry.
Contact Information
Website
www.uaslabs.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Primary Office
- 555 North 72nd Avenue
- Wausau, WI 54401
- United States
+1 (715) 000-0000
UAS Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
UAS Laboratories Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Manufacturer of probiotic products intended to provide trusted probiotic based facilities through the creative applicati
Pharmaceuticals
Wausau, WI
230
As of 2020
000.00
0000
0000-00-00
000000&0
000.00
000000
prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
000000000000000
Somerset, United Kingdom
000
As of 0000
0000
0000-00-00
000000&0
Add Comparison
UAS Laboratories Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 0000000000 0000000 | Corporate Backed or Acquired | Somerset, United Kingdom | 000 | 000000&0 |
UAS Laboratories Patents
UAS Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3067056-A1 | Bacterial compositions for prophylaxis and treatment of degenerative disease | Withdrawn | 01-May-2009 | 0000000000 | 0 |
| JP-2012525338-A | Bacterial composition for the prevention and treatment of degenerative diseases | Granted | 01-May-2009 | 0000000000 | 0 |
| CA-2796929-C | Bacterial compositions for prophylaxis and treatment of degenerative disease | Active | 01-May-2009 | 0000000000 | |
| US-10660857-B2 | Bacterial compositions for prophylaxis and treatment of degenerative disease | Active | 01-May-2009 | 0000000000 | 0 |
| US-20110217368-A1 | Bacterial compositions for prophylaxis and treatment of degenerative disease | Granted | 01-May-2009 | A61K35/744 | 0 |
UAS Laboratories Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Ronald Pillsbury | Chief Operating Officer | ||
| Lynn White | Senior Controller | ||
| Lawrence Hobermann | Medical Director | ||
| Sita Dash Ph.D | Founder |
UAS Laboratories Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
UAS Laboratories Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
UAS Laboratories Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 03-Apr-2018 | 0000000000 | Drug Discovery | 00000 000 | |
| 00000000000 ( | 02-Dec-2014 | 0000000000 | Buildings and Property | 00000 000 | |
| APN Labs | 12-Nov-2010 | Merger/Acquisition | Pharmaceuticals | 0000 0000 |